<DOC>
	<DOCNO>NCT00813969</DOCNO>
	<brief_summary>The study investigator-run , open-label Phase 1 safety study autologous mesenchymal stem cell transplantation , involve approximately 24 ambulatory participant relapse form MS ( approximately equal number relapsing-remitting secondary progressive/ progressive relapse MS ) evidence involvement anterior afferent visual system .</brief_summary>
	<brief_title>Autologous Mesenchymal Stem Cell ( MSC ) Transplantation MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Age 18 55 , inclusive . Diagnosis MS Relapsing form MS ( relapsingremitting , secondary progressive , progressiverelapsing course ) . EDSS score 3.06.5 , inclusive . ( Must able walk ) Active disease prior 24 month . Documented evidence involvement anterior afferent visual system : previous optic neuritis , optic atrophy afferent pupillary defect exam , RNFL thickness OCT &lt; LLN least one eye OR document VEP latency least 1 eye . Cranial MRI scan demonstrating T2hyperintense lesion satisfy diagnostic criterion MS Ability perform component test MSFC ( T25FW , 9HPT , PASAT3 ) . Ability perform SLCLA . Has give write informed consent participate study . A clinically significant infectious illness ( e.g. , cellulitis , abscess , pneumonia , septicemia ) within 30 day Screening Visit . History cancer basal cell carcinoma skin . History laboratory result indicative significant cardiac , endocrine , hematologic , hepatic , immunologic , infectious , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , neoplastic , disorder opinion Principal Investigator would preclude safe performance BM aspiration , infusion autologous MSCs , performance plan study assessment . Abnormal blood test exceed designate limit . Positive screening test hepatitis B , hepatitis C , HIV 1 &amp; 2 , HTLV I/II , CMV , West Nile virus , syphilis , blood parasite infection . Clinically significant abnormality chest Xray . Clinically significant abnormality EKG . Oxygensaturation &lt; 90 % room air . History alcohol drug abuse within one year . Any metallic material electronic device body , condition precludes participant undergo MRI Gd administration . Uncontrolled glaucoma ocular condition precludes perform OCT interpret result . MS relapse onset within 30 day prior Screening Visit participant stabilize previous relapse time Screening Visit . Current treatment investigational MS disease therapy . Prior treatment : Total lymphoid irradiation . Cladribine . Tcell Tcell receptor vaccination . Campath1h ( alemtuzumab ) . Rituxan ( rituximab ) . Prior treatment within three month : Tysabri ( natalizumab ) . Gilenya ( Fingolimod/FTY720 ) . Zenapax ( daclizumab ) . Cytoxan ( cyclophosphamide ) . Novantrone ( mitoxantrone ) . Cyclosporine . CellCept ( mycophenolate mofetil ) . Imuran ( azathioprine ) . Rheumatrex ( methotrexate ) . IV gamma globulin . Plasma exchange . Prior treatment within one month : Systemic corticosteroid daily dose equivalent Prednisone 60 mg great . Female participant postmenopausal least one year , surgically sterile , willing practice effective contraception . Nursing mother , pregnant woman , woman plan become pregnant study . Male participant willing practice effective contraception . Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) , opinion Principal Investigator , likely affect participant 's ability comply study protocol . Any reason , opinion Principal Investigator , make participant unsuitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mesenchymal Stem Cell</keyword>
	<keyword>MSC</keyword>
	<keyword>Autologous</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>